AOK RHEINLANDPFALZSAARLAND THE HEALTH FUND

Open House Discount Contracts for Alfacalcidol

This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical Alfacalcidol, in accordance with specific regulations, for the period from February 1, 2026, to January 31, 2028. Suppliers can enter into contracts at any time during this period, followi

Open House Discount Contracts for Olmesartan and Hydrochlorothiazide

This contract opportunity involves the establishment of non-exclusive discount contracts for the medications Olmesartan and Hydrochlorothiazide. These contracts will be in effect from February 1, 2026, to January 31, 2028, and can be signed at any time during this period (open-house model). Please n

Open House Discount Contracts for Naproxen and Esomeprazole

This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical products Naproxen and Esomeprazole, in accordance with German social law. The contracts will be valid from February 1, 2026, to January 31, 2028, and suppliers can enter into contracts at

Open House Discount Contracts for Glatiramer Acetate

This contract opportunity involves the establishment of non-exclusive discount contracts for the medication Glatiramer Acetate, specifically for pre-filled syringes. The contracts will be in effect from February 1, 2026, to January 31, 2028, with the option for suppliers to enter into contracts at a

Open House Discount Contracts for Bexarotene Medicines in Germany

This contract opportunity involves the establishment of non-exclusive discount contracts for medicines containing the active ingredient Bexarotene, in accordance with German social law. The contracts will be valid from December 1, 2025, to November 30, 2027, and can be signed at any time during this

Published 15 Oct 2025

Open House Discount Contracts for Rivaroxaban

This contract opportunity involves the establishment of non-exclusive discount contracts for the medication Rivaroxaban, specifically for film-coated tablets excluding the 2.5 mg strength. The contracts will be in effect from October 1, 2025, to September 30, 2027, with the option for suppliers to e

Published 21 Aug 2025

Open House Discount Contracts for Tramadol and Paracetamol

This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical products Tramadol and Paracetamol, in accordance with German social law. The contracts will be valid from October 1, 2025, to September 30, 2027, and suppliers can enter into contracts at

Published 5 Aug 2025

Open House Discount Contracts for Olodaterol and Tiotropium Bromide

This contract opportunity involves the establishment of non-exclusive discount contracts for medications containing the active ingredients Olodaterol and Tiotropium Bromide. The contracts will be in effect from October 1, 2025, to September 30, 2027, with the possibility of entering into contracts a

Published 5 Aug 2025

Open House Discount Contracts for Somatropin

This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical product Somatropin, classified under ATC code H01AC01. The contracts will be valid from July 1, 2025, to June 30, 2027, and suppliers can enter into contracts at any time during this perio

Published 18 May 2025

Open House Discount Contracts for Denosumab (Xgeva)

This contract opportunity involves the establishment of non-exclusive discount agreements for the pharmaceutical product Denosumab, marketed as Xgeva, in accordance with German social law. The contracts will be valid from July 1, 2025, to June 30, 2027, and suppliers can enter into agreements at any